Status:

COMPLETED

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

Lead Sponsor:

Tanabe Pharma Corporation

Conditions:

Dyslipidemia

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to assess the safety and tolerability of single doses of TA-8995 in healthy Caucasian and Japanese volunteers.

Eligibility Criteria

Inclusion

  • Caucasian men aged 18-55 years and ≥65 years
  • Women of non-childbearing potential
  • Japanese men aged 18-55 years
  • Subjects were deemed healthy on the basis of medical history, physical examination, Electrocardiogram (ECG), vital signs and safety tests of blood and urine
  • Subjects were able to give fully informed written consent

Exclusion

  • HDL-C level ≥2.59 mmol/L
  • Abnormal Holter ECG
  • Family history of long QT syndrome, hypokalaemia or Torsade de Pointes
  • Vital signs or 12-lead ECG values outside the acceptable range
  • Positive tests for hepatitis B and C, HIV 1 and 2
  • Positive urine pregnancy test (women only)
  • Severe adverse reaction or allergy to any drug
  • Drug or alcohol abuse
  • Smoking within the 6 months before dosing with TA-8995 (Caucasian subjects), or smoking more than 10 cigarettes daily (Japanese subjects)
  • Over-the-counter or prescribed medication up to 7 days or 5 half-lives (whichever was longer) before dosing with TA-8995
  • Consuming food or drinks containing grapefruit or cranberry within the 7 days before dosing
  • Participation in other clinical trials, or loss of more than 450 mL blood within the previous 3 months
  • Clinically relevant abnormal findings at the screening assessment
  • Clinically relevant abnormal medical history or concurrent medical condition
  • Possibility that volunteer would not cooperate

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2009

Estimated Enrollment :

96 Patients enrolled

Trial Details

Trial ID

NCT01878474

Start Date

March 1 2008

End Date

June 1 2009

Last Update

June 17 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hammersmith Medicines Research (HMR)

London, United Kingdom, NW10 7EW